Effects of Oral L-Carnitine Administration in Narcolepsy Patients: A Randomized, Double-Blind, Cross-Over and Placebo-Controlled Trial

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Miyagawa, Taku ^a   Kawamura, Hiromi ^b   Obuchi, Mariko ^b   Ikesaki, Asuka ^b   Ozaki, Akiko ^c   Tokunaga, Katsushi ^a   Inoue, Yuichi ^d,e   Honda, Makoto ^d,f  

^a UNIVERSITY OF TOKYO   (Japan)

^b Clinical Trial Operations Division   (Japan)

^c TOHO UNIVERSITY   (Japan)

^d NEUROPSYCHIATRIC RESEARCH INSTITUTE   (Japan)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

^f TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; CARNITINE; CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE IB; HLA DQB1 ANTIGEN; MESSENGER RNA; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPWORTH SLEEPINESS SCALE; FATTY ACID OXIDATION; FEMALE; HUMAN; LIPID BLOOD LEVEL; MALE; NARCOLEPSY; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SLEEP TIME; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ADULT; CARNITINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FATTY ACIDS; FEMALE; HUMANS; MALE; NARCOLEPSY; OXIDATION-REDUCTION; PLACEBOS;

EID: 84872508153     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053707     Document Type: Article

References (42)

1. Honda Y, Doi Y, Ninomiya R, Ninomiya C, (1986) Increased frequency of non-insulin-dependent diabetes mellitus among narcoleptic patients. Sleep 9: 254-259.
2. Schuld A, Hebebrand J, Geller F, Pollmacher T, (2000) Increased body-mass index in patients with narcolepsy. Lancet 355: 1274-1275.
3. Dahmen N, Bierbrauer J, Kasten M, (2001) Increased prevalence of obesity in narcoleptic patients and relatives. Eur Arch Psychiatry Clin Neurosci 251: 85-89.
4. Kok SW, Overeem S, Visscher TL, Lammers GJ, Seidell JC, et al. (2003) Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res 11: 1147-1154.
5. Schuld A, Beitinger PA, Dalal M, Geller F, Wetter TC, et al. (2002) Increased body mass index (BMI) in male narcoleptic patients, but not in HLA-DR2-positive healthy male volunteers. Sleep Med 3: 335-339.
6. Poli F, Plazzi G, Di Dalmazi G, Ribichini D, Vicennati V, et al. (2009) Body mass index-independent metabolic alterations in narcolepsy with cataplexy. Sleep 32: 1491-1497.
7. Mignot E, (1998) Genetic and familial aspects of narcolepsy. Neurology 50: S16-22.
8. Lin L, Faraco J, Li R, Kadotani H, Rogers W, et al. (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98: 365-376.
9. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, et al. (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98: 437-451.
10. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, et al. (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6: 991-997.
11. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, et al. (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27: 469-474.
12. Juji T, Satake M, Honda Y, Doi Y, (1984) HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 24: 316-319.
13. Mignot E, Lin L, Rogers W, Honda Y, Qiu X, et al. (2001) Complex HLA-DR and-DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 68: 686-699.
14. Hallmayer J, Faraco J, Lin L, Hesselson S, Winkelmann J, et al. (2009) Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 41: 708-711.
15. Kornum BR, Kawashima M, Faraco J, Lin L, Rico TJ, et al. (2011) Common variants in P2RY11 are associated with narcolepsy. Nat Genet 43: 66-71.
16. Miyagawa T, Kawashima M, Nishida N, Ohashi J, Kimura R, et al. (2008) Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 40: 1324-1328.
17. Miyagawa T, Miyadera H, Tanaka S, Kawashima M, Shimada M, et al. (2011) Abnormally low serum acylcarnitine levels in narcolepsy patients. Sleep 34: 349-353A.
18. McGarry JD, Brown NF, (1997) The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 244: 1-14.
19. Yoshida G, Li MX, Horiuchi M, Nakagawa S, Sakata M, et al. (2006) Fasting-induced reduction in locomotor activity and reduced response of orexin neurons in carnitine-deficient mice. Neurosci Res 55: 78-86.
20. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, et al. (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30: 345-354.
21. Kuwajima M, Fujihara H, Sei H, Umehara A, Sei M, et al. (2007) Reduced Carnitine Level Causes Death from Hypoglycemia: Possible Involvement of Suppression of Hypothalamic Orexin Expression During Weaning Period. Endocr J.
22. Tafti M, Petit B, Chollet D, Neidhart E, de Bilbao F, et al. (2003) Deficiency in short-chain fatty acid beta-oxidation affects theta oscillations during sleep. Nat Genet 34: 320-325.
23. Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, et al. (2002) Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci U S A 99: 2356-2361.
24. Rao KV, Qureshi IA, (1997) Decompensation of hepatic and cerebral acyl-CoA metabolism in BALB/cByJ mice by chronic riboflavin deficiency: restoration by acetyl-L-carnitine. Can J Physiol Pharmacol 75: 423-430.
25. Kido Y, Tamai I, Ohnari A, Sai Y, Kagami T, et al. (2001) Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem 79: 959-969.
26. Takegami M, Suzukamo Y, Wakita T, Noguchi H, Chin K, et al. (2009) Development of a Japanese version of the Epworth Sleepiness Scale (JESS) based on item response theory. Sleep Med 10: 556-565.
27. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K, (1998) Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 51: 1037-1044.
28. Fukuhara S, Ware JE Jr, Kosinski M, Wada S, Gandek B, (1998) Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey. J Clin Epidemiol 51: 1045-1053.
29. Faul F, Erdfelder E, Buchner A, Lang AG, (2009) Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41: 1149-1160.
30. Faul F, Erdfelder E, Lang AG, Buchner A, (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-191.
31. Hutton B, Fergusson D, (2004) Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 80: 1461-1468.
32. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, et al. (1986) Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 9: 519-524.
33. Johns MW, (2000) Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the epworth sleepiness scale: failure of the MSLT as a gold standard. J Sleep Res 9: 5-11.
34. Littner M, Kushida CA, Anderson WM, Bailey D, Berry RB, et al. (2003) Practice parameters for the role of actigraphy in the study of sleep and circadian rhythms: an update for 2002. Sleep 26: 337-341.
35. Kuratsune H, Yamaguti K, Takahashi M, Misaki H, Tagawa S, et al. (1994) Acylcarnitine deficiency in chronic fatigue syndrome. Clin Infect Dis 18 (Suppl 1):: S62-67.
36. Kuratsune H, Yamaguti K, Lindh G, Evengard B, Takahashi M, et al. (1998) Low levels of serum acylcarnitine in chronic fatigue syndrome and chronic hepatitis type C, but not seen in other diseases. Int J Mol Med 2: 51-56.
37. Plioplys AV, Plioplys S, (1995) Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology 32: 132-138.
38. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, et al. (1994) The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121: 953-959.
39. Plioplys AV, Plioplys S, (1997) Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. Neuropsychobiology 35: 16-23.
40. Dauvilliers Y, Bayard S, Shneerson JM, Plazzi G, Myers AJ, et al. (2011) High pain frequency in narcolepsy with cataplexy. Sleep Med 12: 572-577.
41. Schneider C, Fulda S, Schulz H, (2004) Daytime variation in performance and tiredness/sleepiness ratings in patients with insomnia, narcolepsy, sleep apnea and normal controls. J Sleep Res 13: 373-383.
42. Droogleever Fortuyn HA, Fronczek R, Smitshoek M, Overeem S, Lappenschaar M, et al. (2012) Severe fatigue in narcolepsy with cataplexy. J Sleep Res 21: 163-169.